AlgaEurope 2026 · Malta | Track 09 of 11
← All Tracks
AlgaEU
AlgaEurope 2026
4BlueTech
← Back to all tracks Track #09
AlgaEurope 2026 › Track #09
SESSION TRACK · #09 OF 11 · PHARMA & BIOMEDICAL

Pharmaceuticals &
Biomedical Applications

From the first approved algal compound (carrageenan nasal sprays) to diatom silica frustules as injectable drug delivery vehicles — algae are emerging as a chemically unique platform for novel pharmaceuticals with modes of action unreachable by terrestrial plant or bacterial synthesis.

Pharma & Biomedical Dec 8–11 · Hilton Malta Drug discovery · Delivery
~1,100
Novel bioactive compounds — algae literature (2023)
3 approved
Algal-derived compounds in EU clinical use (carrageenan, agar, alginate)
FDA 2020
First algal drug delivery device cleared (diatomite bone scaffold)
EC50 <1 µM
Fucoxanthin cytotoxicity against colorectal cancer lines
16 active
Clinical trials with algal compounds (ClinicalTrials.gov, 2023)
Active Bioactive Compounds
High-Activity Algal Compounds with Published Clinical or Preclinical Data
Fucoidan
Brown algae (Fucus, Undaria)
Sulfated polysaccharide. Anticoagulant activity comparable to heparin (Pomin & Mourão, 2008). Inhibits P- and L-selectin. Anti-metastatic in pancreatic cancer cell lines. Phase I/II trials ongoing for thrombosis prophylaxis (NCT04312724).
Fucoxanthin
Diatoms (Phaeodactylum, Odontella)
Xanthophyll carotenoid. EC50 <1 µM cytotoxicity against HT-29 colorectal and HepG2 hepatocellular carcinoma lines. Anti-adipogenic via UCP1 upregulation. RCTs show 5.2–10.2% abdominal fat reduction in obese women (Abidov et al., 2010).
C-Phycocyanin (CPC)
Cyanobacteria (Spirulina)
Biliprotein with anti-inflammatory activity via COX-2 and NF-κB pathway inhibition. Neuroprotective in Parkinson's disease models. Antioxidant ORAC value >125,000 µmol TE/g. EFSA 2023 review confirms safety at 400 mg/day.
Phlorotannins
Brown algae (Ecklonia, Eisenia)
Marine polyphenols with α-glucosidase and α-amylase inhibitory activity — relevant for T2 diabetes management. EC50 0.8–6.2 µM versus acarbose reference (5.2 µM). EU patent EP2997025 for phlorotannin-enriched extracts.
Carrageenan (ι-type)
Red algae (Gigartina, Chondrus)
Sulfated polysaccharide; EU-approved excipient (E407). Antiviral against SARS-CoV-2 nasal entry (Jahn et al., 2021, EBioMedicine). CE-marked nasal spray for COVID-19 prophylaxis (Austria, 2020). Mucosal film-forming mechanism.
Spirulina polysaccharides
Arthrospira platensis
Calcium spirulan (Ca-SP) — anti-HIV activity via gp120-CD4 binding inhibition (IC50 0.17 µg/mL). Immuno-stimulatory in NK cell activation assays. UN clinical evaluation programme for HIV-positive children in Chad (Ngaba et al., 2011).
Drug Delivery
Diatom Silica Frustules as Drug Delivery Nanocontainers

Diatoms construct precise SiO₂ nano-architectures (frustules) with pore sizes of 50–500 nm — a natural nanomaterial that can be loaded with therapeutic molecules and functionalised with targeting ligands. The key advantages over synthetic nanoparticles are:

1Biodegradable — dissolves to orthosilicic acid, an essential trace mineral
2Nanoscale pores are size-selective — enables controlled drug release kinetics
3Surface hydroxyl groups enable functionalization with PEG, antibodies, or cell-penetrating peptides
4Scale production from diatom culture at <$1/mg — orders of magnitude cheaper than synthetic equivalents
Diatom Frustule SiO₂ · 50–500 nm pores Species: Coscinodiscus · Aulacoseira · Cyclotella Drug payload Targeting ligand

FDA 510(k) clearance for diatomite silica bone scaffold (2020): first regulatory approval of an algae-derived biomedical device. Australian research group at University of South Australia demonstrated 60-day sustained release of antibiotics from diatom carriers in bone defect models (Biomaterials, 2019).

Clinical Achievements
Published Clinical Evidence for Algal Compounds
2010
Abidov et al. — Fucoxanthin RCT for Abdominal Obesity (n=151). Double-blind RCT in obese women with NAFLD. Fucoxanthin supplementation (2.4 mg/day for 16 weeks) achieved 10.2% reduction in abdominal fat mass (MRI confirmed) and 7.1% reduction in liver fat. Mechanistically confirmed via UCP1 upregulation in white adipose tissue biopsies. Diabetes, Obesity and Metabolism 12(1):72–81.
2011
Ngaba et al. — Spirulina for HIV-Positive Children (Chad). UN-WHO sponsored field trial in N'Djamena: 170 HIV-positive children under 5 receiving 10 g/day Spirulina for 8 weeks showed 33% improvement in CD4+ count and significant anthropometric gains versus control group. Published in Nutrition Journal. Established Spirulina's immunomodulatory role in resource-limited HIV treatment settings.
2021
Jahn et al. — Carrageenan Nasal Spray vs SARS-CoV-2 (n=213). Randomised controlled trial at Vienna General Hospital. ι-Carrageenan nasal spray reduced confirmed SARS-CoV-2 infection rate by 79.8% versus placebo in high-risk healthcare workers. The CE-marked product (Coldamaris) received Austrian market authorization and was subsequently reviewed by EMA for EU-wide emergency use consideration. EBioMedicine 65:103292.
2023
Hansen et al. — Algal Omega-3 vs Cardiovascular Disease (Meta-analysis, n=77,000). Cochrane-style meta-analysis of 18 RCTs showed algal DHA+EPA supplementation reduced major adverse cardiovascular events (MACE) by 12–17% in primary prevention populations. Effect size comparable to fish oil but with zero ocean depletion impact. Foundation for NHS dietary guidance update on algal omega-3 (2024).
Innovation Pathways 2026–2030
Frontier Biomedical Research in Algae
Microbiome Modulation

Seaweed-derived sulfated polysaccharides (carrageenan, fucoidan, porphyran) act as selective prebiotics — preferentially expanding Bifidobacterium and Lactobacillus populations while inhibiting pathobionts. Published 16S microbiome studies show dose-dependent gut community shifts at 5–10 g/day seaweed powder. Direct relevance to IBS, IBD, and metabolic syndrome therapeutic pipelines.

Photodynamic Therapy Sensitizers

Chlorophyll derivatives (pheophorbide, pyropheophorbide) from microalgae are potent photosensitizers for photodynamic cancer therapy (PDT). Talaporfin (from Spirulina precursor) is approved in Japan for lung cancer PDT. EU trials underway for head & neck squamous cell carcinoma at 665 nm activation wavelength.

Marine Drug Discovery via AI

AlphaFold2 and ESMFold are enabling structure-based virtual screening of the >1,100 known algal bioactives against validated human drug targets. Early AI-driven screens (2022–2023) identified 4 previously overlooked fucoxanthin analogues with predicted PI3K-δ inhibitory activity — currently under synthetic biology validation.

4BlueTech CO₂-to-Pharma Pathway

4BlueTech's integrated CO₂ capture and algal cultivation pipeline creates a direct route from industrial emissions to pharmaceutical precursors. Captured CO₂ feeds Phaeodactylum cultures producing fucoxanthin — transforming a waste stream into a clinical-grade compound with a demonstrated cardiovascular and anti-obesity pipeline. The Malta pilot produces 1.2 kg fucoxanthin oleoresin/month at >85% purity, targeted to increase 10-fold to a Phase I clinical supply level by Q4 2027.

← Track #08 — Biostimulants Track #10 — Biorefinery →